TOG Review (RCOG Journal)

MRCOG Part 2

Sexual and Reproductive Health

Update on recurrent vulvovaginal candidiasis

Key Statistics

  • ≥4/yr — Episodes defining RVVC
  • 130 million — Women affected worldwide/yr
  • 80–89% — RVVC due to c. albicans

Don't-miss facts

  1. RVVC = ≥4 episodes/12 months, ≥2 confirmed by culture/microscopy (≥1 by culture)

  2. C. albicans causes 80–89% of RVVC; C. glabrata is inherently azole-resistant – send species ID/sensitivities

  3. Vaginal pH ≤4.5 → favours VVC; >4.5 → favours BV/TV

  4. BASHH induction: fluconazole 150 mg PO every 72h ×3, then weekly ×6 months maintenance (or clotrimazole pessary equivalent)

  5. Fluconazole suppression 93% effective but 80% relapse on stopping; 7.5% resistance develops

  6. Avoid oral azoles in pregnancy – use topical clotrimazole; extended 7-day course gives 90% cure vs 50% at 4 days

  7. Breastfeeding OK after single 150 mg fluconazole dose only; avoid repeat/high doses

  8. Watch for hypokalaemia/QT prolongation with multi-dose azoles; topical treatments can damage condoms

Do not treat

Asymptomatic colonisation (up to 20% of women)

Abbreviation Key

  • VVC — vulvovaginal candidiasis
  • HbA1c — glycated haemoglobin
  • RVVC — recurrent vulvovaginal candidiasis
  • NAAT — nucleic acid amplification test
  • BASHH — British Association for Sexual Health and HIV
  • TV — Trichomonas vaginalis
  • MBL — mannose binding lectin
  • BV — bacterial vaginosis

Source: Borland A et al. Update on recurrent vulvovaginal candidiasis. The Obstetrician & Gynaecologist 2021;23:295–300. doi:10.1111/tog.12772

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).

Included with a Pass Package

  • Audio overview of this guideline
  • Practice questions drawn from it
  • AI tutor answers grounded in its text
  • Your own annotations
Start free